Bris­tol My­er­s' CAR-T ther­a­py Breyanzi adds fol­lic­u­lar lym­phoma to list of ap­provals

Just two months af­ter earn­ing an­oth­er ap­proval for its block­buster blood can­cer drug Breyanzi, Bris­tol My­ers Squibb can add an ac­cel­er­at­ed ap­proval to the list …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.